Crystalys Therapeutics (Series A)
Funding Details
Awarder
Inbox
Date Award
October 6, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Funding Amount
$205,000,000
Company Info
Founders
Catalys Pacific, Novo Holdings
Market
Gout treatment
Location
San Diego, California, USA
Coinvestors
Aberdeen Investments, Alexandria Venture Investments, AN Ventures, Catalys Pacific, KB Investments, Lightstone Ventures, Longwood Fund, Novo Holdings, Perceptive, Xontogeny Venture Fund, Pontifax, Prebys Ventures Fund, SR One, Wedbush Healthcare Partners
Company Description

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi.

Links
Website
Back to HomeBack to Biopharmaceuticals DealsView Funding Announcement